Karyopharm Therapeutics Inc. (KPTI) KPIs and segments
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Karyopharm Therapeutics's business
Karyopharm Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product($M) | 30.8 | 29.2 | 32.1 | 32.0 | 29.7 | 21.1 | 29.3 | 29.5 | 28.0 | 26.0 | 25.1 | 30.2 | |
License and Other($M) | 2.66 | 5.90 | 1.99 | 12.0 | 8.25 | 8.96 | 1.29 | 9.27 | 14.8 | 7.12 | 8.69 | 5.80 | |
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-13.
See a number that looks wrong?